CEFPODOXIME PROXETIL - Generic Drug Details

What are the generic sources for cefpodoxime proxetil and what is the scope of freedom to operate?

Cefpodoxime proxetil is the generic ingredient in three branded drugs marketed by Sankyo, Aurobindo Pharma Ltd, Chartwell Rx, Sun Pharm Inds Ltd, Pharmacia And Upjohn, Alkem Labs Ltd, Anda Repository, Aurobindo Pharma, and Sandoz, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for cefpodoxime proxetil. Ten suppliers are listed for this compound.

Summary for CEFPODOXIME PROXETIL

US Patents:	0
Tradenames:	3
Applicants:	9
NDAs:	12
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	83
Clinical Trials:	2
Patent Applications:	4,950
Drug Prices:	Drug price trends for CEFPODOXIME PROXETIL
What excipients (inactive ingredients) are in CEFPODOXIME PROXETIL?	CEFPODOXIME PROXETIL excipients list
DailyMed Link:	CEFPODOXIME PROXETIL at DailyMed

See drug prices for CEFPODOXIME PROXETIL

Recent Clinical Trials for CEFPODOXIME PROXETIL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Entasis Therapeutics	Phase 1
University of Louisville	Early Phase 1
James Graham Brown Cancer Center	Early Phase 1

See all CEFPODOXIME PROXETIL clinical trials

Pharmacology for CEFPODOXIME PROXETIL

Drug Class

Cephalosporin Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for CEFPODOXIME PROXETIL

J01DD	Third-generation cephalosporins
J01D	OTHER BETA-LACTAM ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for CEFPODOXIME PROXETIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Anda Repository	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	065388-001	Nov 14, 2007	AB	RX	No	No
Alkem Labs Ltd	CEFPODOXIME PROXETIL	cefpodoxime proxetil	TABLET;ORAL	210568-002	May 18, 2022	AB	RX	No	No
Aurobindo Pharma Ltd	CEFPODOXIME PROXETIL	cefpodoxime proxetil	FOR SUSPENSION;ORAL	065409-002	Jun 8, 2007		RX	No	Yes

CEFPODOXIME PROXETIL Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Cefpodoxime Proxetil

Introduction to Cefpodoxime Proxetil

Cefpodoxime proxetil is a cephalosporin antibiotic used to treat a variety of bacterial infections, including those affecting the skin, respiratory tract, and urinary system. It is available in various forms such as tablets and powder for suspension, making it versatile for different patient needs[5].

Global Market Size and Forecast

As of 2024, the global cefpodoxime proxetil market is estimated to be valued at USD 15,245.2 million. This market is projected to grow at a compound annual growth rate (CAGR) of 5.00% from 2024 to 2031[1].

Regional Market Analysis

North America

North America dominates the cefpodoxime proxetil market, accounting for approximately 40% of the global revenue in 2024. The region's advanced healthcare infrastructure, high prevalence of bacterial infections, and strong regulatory frameworks contribute to its market leadership. The United States alone accounts for USD 4,811.39 million in sales revenue, with a CAGR of 3% from 2024 to 2031. Canada also plays a significant role, with a sales revenue of USD 731.77 million in 2024[1].

Europe

Europe holds a substantial market share, with a market size of USD 4,573.56 million in 2024. The region is expected to grow at a CAGR of 3.5% from 2024 to 2031. Europe's robust pharmaceutical industry and well-established healthcare system drive the demand for cefpodoxime proxetil[1].

Asia Pacific

The Asia Pacific region is the fastest-growing market for cefpodoxime proxetil, driven by increasing healthcare access, rising prevalence of bacterial infections, and expanding pharmaceutical manufacturing capabilities. The region's market size was estimated at USD 3,506.40 million in 2024 and is expected to grow at a CAGR of 7.0% from 2024 to 2031[1].

Latin America and Middle East & Africa

Latin America accounts for around 5% of the global revenue, with a market size of USD 762.26 million in 2024, and is expected to grow at a CAGR of 4.4% from 2024 to 2031. The Middle East and Africa region holds a smaller but significant share, with a market size of USD 304.90 million in 2024, and a CAGR of 4.7% from 2024 to 2031[1].

Market Drivers

Advancements in Pharmaceutical Formulations

Innovations in pharmaceutical formulations, such as controlled-release formulations and combination therapies, significantly drive the growth of the cefpodoxime proxetil market. These advancements enhance the drug's effectiveness and patient compliance, while modern drug delivery technologies improve bioavailability and minimize side effects[1].

Increasing Geriatric Population

The rising geriatric population, which requires frequent medical interventions, contributes to the demand for cefpodoxime proxetil. Elderly patients are more susceptible to bacterial infections, and the drug's safety profile in this age group supports its widespread use[1][5].

Expanding Healthcare Access

Increasing healthcare access, particularly in emerging markets, fuels the demand for antibiotic treatments like cefpodoxime proxetil. Government initiatives and investments in healthcare infrastructure in regions like Asia Pacific further boost market growth[1].

Market Trends

Antimicrobial Stewardship Programs

The implementation of antimicrobial stewardship programs, which include strategies like intravenous-to-oral conversions and formulary restrictions, is a significant trend. These programs aim to optimize antibiotic use, reduce costs, and combat antibiotic resistance. For instance, a study highlighted that such programs can achieve substantial cost savings while improving patient outcomes[2].

Pediatric and Oral Formulations

The development of new oral and pediatric formulations of cefpodoxime proxetil caters to a broader patient base, including children and the elderly. These formulations enhance patient compliance and expand the drug’s applications in diverse healthcare settings[1].

Market Split by Dosage, Form, Application, and Distribution Channel

• Dosage: The market is segmented based on different dosages, with varying strengths available for different types of infections and patient groups.
• Form: Cefpodoxime proxetil is available in tablets and powder for suspension, each catering to different patient needs and preferences.
• Application: The drug is used to treat a range of bacterial infections, including skin infections, respiratory tract infections, and urinary tract infections.
• Distribution Channel: The market is segmented based on distribution channels such as hospitals, clinics, retail pharmacies, and online pharmacies[1][3].

Competitive Landscape

The cefpodoxime proxetil market is competitive, with several key players operating globally. These companies focus on innovation, regulatory compliance, and market expansion to maintain their market share. The competitive landscape is influenced by factors such as product quality, pricing strategies, and distribution networks[1].

Financial Performance and Projections

The global cefpodoxime proxetil market is valued at USD 15,245.2 million in 2024 and is projected to grow at a CAGR of 5.00% from 2024 to 2031. This growth is driven by increasing demand, advancements in formulations, and expanding healthcare access.

• North America: Expected to grow at a CAGR of 3.2% from 2024 to 2031.
• Europe: Expected to grow at a CAGR of 3.5% from 2024 to 2031.
• Asia Pacific: Expected to grow at a CAGR of 7.0% from 2024 to 2031.
• Latin America: Expected to grow at a CAGR of 4.4% from 2024 to 2031.
• Middle East & Africa: Expected to grow at a CAGR of 4.7% from 2024 to 2031[1].

Key Takeaways

• The global cefpodoxime proxetil market is projected to grow significantly, driven by advancements in pharmaceutical formulations and increasing healthcare access.
• North America and Europe are major markets, while Asia Pacific is the fastest-growing region.
• The drug's safety profile and effectiveness in treating various bacterial infections support its widespread use.
• Antimicrobial stewardship programs and the development of new formulations are key trends shaping the market.

Frequently Asked Questions (FAQs)

1. What is cefpodoxime proxetil used for? Cefpodoxime proxetil is used to treat bacterial infections in various parts of the body, including skin, respiratory tract, and urinary system infections[5].

2. What are the key drivers of the cefpodoxime proxetil market? The key drivers include advancements in pharmaceutical formulations, increasing geriatric population, and expanding healthcare access, particularly in emerging markets[1].

3. Which region is the fastest-growing market for cefpodoxime proxetil? The Asia Pacific region is the fastest-growing market, driven by increasing healthcare access and rising prevalence of bacterial infections[1].

4. What are the common side effects of cefpodoxime proxetil? Common side effects include diarrhea, loose stools, and abdominal or stomach pain. Less common side effects can include joint or muscle pain, itching, and inflammation of the joints[5].

5. How does the market split by dosage and form impact the cefpodoxime proxetil market? The availability of different dosages and forms (tablets and powder for suspension) caters to a broader patient base, enhancing patient compliance and expanding the drug’s applications in diverse healthcare settings[1].

Cited Sources:

1. Cognitive Market Research, "Cefpodoxime Proxetil Market Report 2024 (Global Edition)".
2. Clinical Infectious Diseases, "Is the “Low-Hanging Fruit” Worth Picking for Antimicrobial Stewardship Programs?".
3. Cognitive Market Research, "Cefpodoxime Proxetil Tablets Market Report 2024 (Global Edition)".
4. Verified Market Research, "Cefpodoxime Proxetil Tablets Market Size, Trends & Forecast".
5. Mayo Clinic, "Cefpodoxime (oral route) - Mayo Clinic".